Le Lézard
Classified in: Health
Subjects: CCA, TDS, FVT

Regeneron Announces Upcoming Investor Conference Presentations


TARRYTOWN, N.Y., Nov. 12, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations as follows:

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations.  Replays of the webcasts will be archived on the Company's website for at least 30 days.

About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.  Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.  Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through its proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:
Investor Relations
Justin Holko
914.847.7786
[email protected]

Corporate Communications
Hala Mirza
914.847.3422
[email protected]

SOURCE Regeneron Pharmaceuticals, Inc.


These press releases may also interest you

at 13:04
Concept Medical, a pioneer in innovative drug delivery technologies, proudly announces the commencement of its groundbreaking IDE clinical study, "MAGICAL-ISR" using MagicTouch ? Sirolimus drug coated balloon (DCB), for the management of in-stent...

at 12:30
The American College of Physicians (ACP) today released an update of its 2017 guideline with clinical recommendations for the use of newer pharmacological treatments of adults with Type 2 diabetes. The clinical guideline is based on the best...

at 12:10
Pieris Pharmaceuticals, Inc. today announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024. The Company's...

at 12:00
Maintaining asthma medication and asthma control leads to safer perinatal outcomes for pregnant women according to new research published in The Journal of Allergy and Clinical Immunology: In Practice (JACI: In Practice), an official journal of the...

at 11:45
Today at ACP's annual meeting, Internal Medicine Meeting 2024, Annals of Internal Medicine presented three breaking scientific research articles during a live scientific plenary session that featured the authors of those articles. The articles were...

at 11:43
- Cochlear Limited , the global leader in implantable hearing...



News published on and distributed by: